APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neurofibromatoses Type II Therapecutics

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neurofibromatoses Type II Therapecutics Industry Growth and Trends Forecast to 2032

Report ID 174016500122 December 202594 pages

Choose your research edition.

Industry ResearchNeurofibromatoses Type II Therapecutics Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurofibromatoses Type II Therapecutics Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Neurofibromatoses Type II Therapecutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurofibromatoses Type II Therapecutics Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurofibromatoses Type II Therapecutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Neurofibromatoses Type II Therapecutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neurofibromatoses Type II Therapecutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neurofibromatoses Type II Therapecutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurofibromatoses Type II Therapecutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neurofibromatoses Type II Therapecutics include AstraZeneca Plc, Recursion Pharmaceuticals Inc, Plex Pharmaceuticals Inc, Lixte Biotechnology Holdings Inc, Beta Pharma Inc and Arno Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neurofibromatoses Type II Therapecutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neurofibromatoses Type II Therapecutics market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neurofibromatoses Type II Therapecutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neurofibromatoses Type II Therapecutics.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Neurofibromatoses Type II Therapecutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neurofibromatoses Type II Therapecutics Market by Company

AstraZeneca Plc

Recursion Pharmaceuticals Inc

Plex Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

Beta Pharma Inc

Arno Therapeutics Inc

Neurofibromatoses Type II Therapecutics Segment by Type

LB-205

LB-201

Icotinib Hydrochloride

FRAX-597

AR-42

Others

Neurofibromatoses Type II Therapecutics Segment by Application

Clinic

Hospital

Home Care

Neurofibromatoses Type II Therapecutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurofibromatoses Type II Therapecutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurofibromatoses Type II Therapecutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurofibromatoses Type II Therapecutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neurofibromatoses Type II Therapecutics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Neurofibromatoses Type II Therapecutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of LB-205 Table 2. Major Company of LB-201 Table 3. Major Company of Icotinib Hydrochloride Table 4. Major Company of FRAX-597 Table 5. Major Company of AR-42 Table 6. Major Company of Others Table 7. Global Neurofibromatoses Type II Therapecutics Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Neurofibromatoses Type II Therapecutics Sales by Type (2021-2026) & (k units) Table 9. Global Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Type (2021-2026) Table 10. Global Neurofibromatoses Type II Therapecutics Sales by Type (2021-2026) & (US$ Million) Table 11. Global Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Type (2021-2026) Table 12. Global Neurofibromatoses Type II Therapecutics Price by Type (2021-2026) & (US$/unit) Table 13. Global Neurofibromatoses Type II Therapecutics Sales by Type (2027-2032) & (k units) Table 14. Global Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Type (2027-2032) Table 15. Global Neurofibromatoses Type II Therapecutics Sales by Type (2027-2032) & (US$ Million) Table 16. Global Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Type (2027-2032) Table 17. Global Neurofibromatoses Type II Therapecutics Price by Type (2027-2032) & (US$/unit) Table 18. North America Neurofibromatoses Type II Therapecutics Sales by Type (2021-2026) & (k units) Table 19. North America Neurofibromatoses Type II Therapecutics Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Neurofibromatoses Type II Therapecutics Sales by Type (2021-2026) & (k units) Table 21. Europe Neurofibromatoses Type II Therapecutics Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales by Type (2021-2026) & (k units) Table 23. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Neurofibromatoses Type II Therapecutics Sales by Type (2021-2026) & (k units) Table 25. Latin America Neurofibromatoses Type II Therapecutics Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Type (2021-2026) & (k units) Table 27. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Type (2021-2026) & (US$ Million) Table 28. Neurofibromatoses Type II Therapecutics Industry Trends Table 29. Neurofibromatoses Type II Therapecutics Industry Drivers Table 30. Neurofibromatoses Type II Therapecutics Industry Opportunities and Challenges Table 31. Neurofibromatoses Type II Therapecutics Industry Restraints Table 32. Global Neurofibromatoses Type II Therapecutics Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Company (2021-2026) Table 34. Global Neurofibromatoses Type II Therapecutics Sales by Company (2021-2026) & (k units) Table 35. Global Neurofibromatoses Type II Therapecutics Sales Share by Company (2021-2026) Table 36. Global Neurofibromatoses Type II Therapecutics Market Price by Company (2021-2026) & (US$/unit) Table 37. Global Neurofibromatoses Type II Therapecutics Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Neurofibromatoses Type II Therapecutics Major Company Production Sites and Headquarters Table 39. Global Neurofibromatoses Type II Therapecutics Company, Product Type & Application Table 40. Global Neurofibromatoses Type II Therapecutics Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Neurofibromatoses Type II Therapecutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Neurofibromatoses Type II Therapecutics Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Neurofibromatoses Type II Therapecutics Sales by Region (2021-2026) & (k units) Table 45. Global Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Region (2021-2026) Table 46. Global Neurofibromatoses Type II Therapecutics Sales by Region (2021-2026) & (US$ Million) Table 47. Global Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Region (2021-2026) Table 48. Global Neurofibromatoses Type II Therapecutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 49. Global Neurofibromatoses Type II Therapecutics Sales by Region (2027-2032) & (k units) Table 50. Global Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Region (2027-2032) Table 51. Global Neurofibromatoses Type II Therapecutics Sales by Region (2027-2032) & (US$ Million) Table 52. Global Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Region (2027-2032) Table 53. Global Neurofibromatoses Type II Therapecutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 54. Global Neurofibromatoses Type II Therapecutics Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Neurofibromatoses Type II Therapecutics Sales by Application (2021-2026) & (k units) Table 56. Global Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Application (2021-2026) Table 57. Global Neurofibromatoses Type II Therapecutics Sales by Application (2021-2026) & (US$ Million) Table 58. Global Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Application (2021-2026) Table 59. Global Neurofibromatoses Type II Therapecutics Price by Application (2021-2026) & (US$/unit) Table 60. Global Neurofibromatoses Type II Therapecutics Sales by Application (2027-2032) & (k units) Table 61. Global Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Application (2027-2032) Table 62. Global Neurofibromatoses Type II Therapecutics Sales by Application (2027-2032) & (US$ Million) Table 63. Global Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Application (2027-2032) Table 64. Global Neurofibromatoses Type II Therapecutics Price by Application (2027-2032) & (US$/unit) Table 65. North America Neurofibromatoses Type II Therapecutics Sales by Application (2021-2026) & (k units) Table 66. North America Neurofibromatoses Type II Therapecutics Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Neurofibromatoses Type II Therapecutics Sales by Application (2021-2026) & (k units) Table 68. Europe Neurofibromatoses Type II Therapecutics Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales by Application (2021-2026) & (k units) Table 70. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Neurofibromatoses Type II Therapecutics Sales by Application (2021-2026) & (k units) Table 72. Latin America Neurofibromatoses Type II Therapecutics Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Application (2021-2026) & (k units) Table 74. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Application (2021-2026) & (US$ Million) Table 75. AstraZeneca Plc Company Information Table 76. AstraZeneca Plc Business Overview Table 77. AstraZeneca Plc Neurofibromatoses Type II Therapecutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. AstraZeneca Plc Neurofibromatoses Type II Therapecutics Product Portfolio Table 79. AstraZeneca Plc Recent Development Table 80. Recursion Pharmaceuticals Inc Company Information Table 81. Recursion Pharmaceuticals Inc Business Overview Table 82. Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Portfolio Table 84. Recursion Pharmaceuticals Inc Recent Development Table 85. Plex Pharmaceuticals Inc Company Information Table 86. Plex Pharmaceuticals Inc Business Overview Table 87. Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Portfolio Table 89. Plex Pharmaceuticals Inc Recent Development Table 90. Lixte Biotechnology Holdings Inc Company Information Table 91. Lixte Biotechnology Holdings Inc Business Overview Table 92. Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Product Portfolio Table 94. Lixte Biotechnology Holdings Inc Recent Development Table 95. Beta Pharma Inc Company Information Table 96. Beta Pharma Inc Business Overview Table 97. Beta Pharma Inc Neurofibromatoses Type II Therapecutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Beta Pharma Inc Neurofibromatoses Type II Therapecutics Product Portfolio Table 99. Beta Pharma Inc Recent Development Table 100. Arno Therapeutics Inc Company Information Table 101. Arno Therapeutics Inc Business Overview Table 102. Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Product Portfolio Table 104. Arno Therapeutics Inc Recent Development Table 105. North America Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 106. North America Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026) & (k units) Table 107. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Country (2021-2026) Table 108. North America Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2027-2032) & (k units) Table 109. North America Neurofibromatoses Type II Therapecutics Sales Market Share Forecast by Country (2027-2032) Table 110. North America Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 111. North America Neurofibromatoses Type II Therapecutics Market Size by Country (2021-2026) & (US$ Million) Table 112. North America Neurofibromatoses Type II Therapecutics Market Share by Country (2021-2026) Table 113. North America Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 114. North America Neurofibromatoses Type II Therapecutics Market Share Forecast by Country (2027-2032) Table 115. Europe Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 116. Europe Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026) & (k units) Table 117. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Country (2021-2026) Table 118. Europe Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2027-2032) & (k units) Table 119. Europe Neurofibromatoses Type II Therapecutics Sales Market Share Forecast by Country (2027-2032) Table 120. Europe Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 121. Europe Neurofibromatoses Type II Therapecutics Market Size by Country (2021-2026) & (US$ Million) Table 122. Europe Neurofibromatoses Type II Therapecutics Market Share by Country (2021-2026) Table 123. Europe Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 124. Europe Neurofibromatoses Type II Therapecutics Market Share Forecast by Country (2027-2032) Table 125. Asia-Pacific Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 126. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026) & (k units) Table 127. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Market Share by Country (2021-2026) Table 128. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2027-2032) & (k units) Table 129. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Market Share Forecast by Country (2027-2032) Table 130. Asia-Pacific Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 131. Asia-Pacific Neurofibromatoses Type II Therapecutics Market Size by Country (2021-2026) & (US$ Million) Table 132. Asia-Pacific Neurofibromatoses Type II Therapecutics Market Share by Country (2021-2026) Table 133. Asia-Pacific Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 134. Asia-Pacific Neurofibromatoses Type II Therapecutics Market Share Forecast by Country (2027-2032) Table 135. Latin America Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 136. Latin America Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026) & (k units) Table 137. Latin America Neurofibromatoses Type II Therapecutics Sales Market Share by Country (2021-2026) Table 138. Latin America Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2027-2032) & (k units) Table 139. Latin America Neurofibromatoses Type II Therapecutics Sales Market Share Forecast by Country (2027-2032) Table 140. Latin America Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 141. Latin America Neurofibromatoses Type II Therapecutics Market Size by Country (2021-2026) & (US$ Million) Table 142. Latin America Neurofibromatoses Type II Therapecutics Market Share by Country (2021-2026) Table 143. Latin America Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 144. Latin America Neurofibromatoses Type II Therapecutics Market Share Forecast by Country (2027-2032) Table 145. Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 146. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026) & (k units) Table 147. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Market Share by Country (2021-2026) Table 148. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2027-2032) & (k units) Table 149. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Market Share Forecast by Country (2027-2032) Table 150. Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 151. Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size by Country (2021-2026) & (US$ Million) Table 152. Middle East and Africa Neurofibromatoses Type II Therapecutics Market Share by Country (2021-2026) Table 153. Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 154. Middle East and Africa Neurofibromatoses Type II Therapecutics Market Share Forecast by Country (2027-2032) Table 155. Key Raw Materials Table 156. Raw Materials Key Suppliers Table 157. Neurofibromatoses Type II Therapecutics Distributors List Table 158. Neurofibromatoses Type II Therapecutics Customers List Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Neurofibromatoses Type II Therapecutics Image Figure 2. Global Neurofibromatoses Type II Therapecutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurofibromatoses Type II Therapecutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurofibromatoses Type II Therapecutics Sales (2021-2032) & (k units) Figure 5. LB-205 Image Figure 6. Global LB-205 Sales YoY Growth (2021-2032) & (k units) Figure 7. LB-201 Image Figure 8. Global LB-201 Sales YoY Growth (2021-2032) & (k units) Figure 9. Icotinib Hydrochloride Image Figure 10. Global Icotinib Hydrochloride Sales YoY Growth (2021-2032) & (k units) Figure 11. FRAX-597 Image Figure 12. Global FRAX-597 Sales YoY Growth (2021-2032) & (k units) Figure 13. AR-42 Image Figure 14. Global AR-42 Sales YoY Growth (2021-2032) & (k units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 17. Global Neurofibromatoses Type II Therapecutics Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Neurofibromatoses Type II Therapecutics Market Share by Type 2025 VS 2032 Figure 19. North America Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Type in 2025 Figure 20. North America Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Type in 2025 Figure 21. Europe Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Type in 2025 Figure 22. Europe Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Type in 2025 Figure 25. Latin America Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Neurofibromatoses Type II Therapecutics Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 33. Hospital Image Figure 34. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 35. Home Care Image Figure 36. Global Home Care Sales YoY Growth (2021-2032) & (k units) Figure 37. Global Neurofibromatoses Type II Therapecutics Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Neurofibromatoses Type II Therapecutics Market Share by Application 2025 VS 2032 Figure 39. North America Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Application in 2025 Figure 40. North America Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Application in 2025 Figure 41. Europe Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Application in 2025 Figure 42. Europe Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Application in 2025 Figure 45. Latin America Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Market Share in Value by Application in 2025 Figure 49. North America Neurofibromatoses Type II Therapecutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. North America Neurofibromatoses Type II Therapecutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Neurofibromatoses Type II Therapecutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Neurofibromatoses Type II Therapecutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Neurofibromatoses Type II Therapecutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Europe Neurofibromatoses Type II Therapecutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Neurofibromatoses Type II Therapecutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Neurofibromatoses Type II Therapecutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Neurofibromatoses Type II Therapecutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Neurofibromatoses Type II Therapecutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Neurofibromatoses Type II Therapecutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Latin America Neurofibromatoses Type II Therapecutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Neurofibromatoses Type II Therapecutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Neurofibromatoses Type II Therapecutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 66. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Neurofibromatoses Type II Therapecutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Neurofibromatoses Type II Therapecutics Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Neurofibromatoses Type II Therapecutics Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • LB-205
  • LB-201
  • Icotinib Hydrochloride
  • FRAX-597
  • AR-42
  • Others
Applications
  • Clinic
  • Hospital
  • Home Care
Companies covered
  • AstraZeneca Plc
  • Recursion Pharmaceuticals Inc
  • Plex Pharmaceuticals Inc
  • Lixte Biotechnology Holdings Inc
  • Beta Pharma Inc
  • Arno Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neurofibromatoses Type II Therapecutics Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Neurofibromatoses Type II Therapecutics Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Neurofibromatoses Type II Therapecutics Market by Type
  6. 1.3.1 LB-205
  7. 1.3.2 LB-201
  8. 1.3.3 Icotinib Hydrochloride
  9. 1.3.4 FRAX-597
  10. 1.3.5 AR-42
  11. 1.3.6 Others
  12. 1.4 Global Neurofibromatoses Type II Therapecutics Market Size by Type
  13. 1.4.1 Global Neurofibromatoses Type II Therapecutics Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Neurofibromatoses Type II Therapecutics Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Neurofibromatoses Type II Therapecutics Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Neurofibromatoses Type II Therapecutics Industry Trends
  2. 2.2 Neurofibromatoses Type II Therapecutics Industry Drivers
  3. 2.3 Neurofibromatoses Type II Therapecutics Industry Opportunities and Challenges
  4. 2.4 Neurofibromatoses Type II Therapecutics Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Neurofibromatoses Type II Therapecutics Revenue (2021-2026)
  2. 3.2 Global Top Players by Neurofibromatoses Type II Therapecutics Sales (2021-2026)
  3. 3.3 Global Top Players by Neurofibromatoses Type II Therapecutics Price (2021-2026)
  4. 3.4 Global Neurofibromatoses Type II Therapecutics Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neurofibromatoses Type II Therapecutics Major Company Production Sites & Headquarters
  6. 3.6 Global Neurofibromatoses Type II Therapecutics Company, Product Type & Application
  7. 3.7 Global Neurofibromatoses Type II Therapecutics Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neurofibromatoses Type II Therapecutics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neurofibromatoses Type II Therapecutics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neurofibromatoses Type II Therapecutics Tier 1, Tier 2, and Tier 3
4 Neurofibromatoses Type II Therapecutics Regional Status and Outlook
  1. 4.1 Global Neurofibromatoses Type II Therapecutics Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Neurofibromatoses Type II Therapecutics Historic Market Size by Region
  3. 4.2.1 Global Neurofibromatoses Type II Therapecutics Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Neurofibromatoses Type II Therapecutics Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Neurofibromatoses Type II Therapecutics Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Neurofibromatoses Type II Therapecutics Forecasted Market Size by Region
  7. 4.3.1 Global Neurofibromatoses Type II Therapecutics Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Neurofibromatoses Type II Therapecutics Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Neurofibromatoses Type II Therapecutics Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Neurofibromatoses Type II Therapecutics by Application
  1. 5.1 Neurofibromatoses Type II Therapecutics Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Home Care
  5. 5.2 Global Neurofibromatoses Type II Therapecutics Market Size by Application
  6. 5.2.1 Global Neurofibromatoses Type II Therapecutics Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Neurofibromatoses Type II Therapecutics Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Neurofibromatoses Type II Therapecutics Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 AstraZeneca Plc
  2. 6.1.1 AstraZeneca Plc Company Information
  3. 6.1.2 AstraZeneca Plc Business Overview
  4. 6.1.3 AstraZeneca Plc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 AstraZeneca Plc Neurofibromatoses Type II Therapecutics Product Portfolio
  6. 6.1.5 AstraZeneca Plc Recent Developments
  7. 6.2 Recursion Pharmaceuticals Inc
  8. 6.2.1 Recursion Pharmaceuticals Inc Company Information
  9. 6.2.2 Recursion Pharmaceuticals Inc Business Overview
  10. 6.2.3 Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Portfolio
  12. 6.2.5 Recursion Pharmaceuticals Inc Recent Developments
  13. 6.3 Plex Pharmaceuticals Inc
  14. 6.3.1 Plex Pharmaceuticals Inc Company Information
  15. 6.3.2 Plex Pharmaceuticals Inc Business Overview
  16. 6.3.3 Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Portfolio
  18. 6.3.5 Plex Pharmaceuticals Inc Recent Developments
  19. 6.4 Lixte Biotechnology Holdings Inc
  20. 6.4.1 Lixte Biotechnology Holdings Inc Company Information
  21. 6.4.2 Lixte Biotechnology Holdings Inc Business Overview
  22. 6.4.3 Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Product Portfolio
  24. 6.4.5 Lixte Biotechnology Holdings Inc Recent Developments
  25. 6.5 Beta Pharma Inc
  26. 6.5.1 Beta Pharma Inc Company Information
  27. 6.5.2 Beta Pharma Inc Business Overview
  28. 6.5.3 Beta Pharma Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Beta Pharma Inc Neurofibromatoses Type II Therapecutics Product Portfolio
  30. 6.5.5 Beta Pharma Inc Recent Developments
  31. 6.6 Arno Therapeutics Inc
  32. 6.6.1 Arno Therapeutics Inc Company Information
  33. 6.6.2 Arno Therapeutics Inc Business Overview
  34. 6.6.3 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Product Portfolio
  36. 6.6.5 Arno Therapeutics Inc Recent Developments
7 North America by Country
  1. 7.1 North America Neurofibromatoses Type II Therapecutics Sales by Country
  2. 7.1.1 North America Neurofibromatoses Type II Therapecutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026)
  4. 7.1.3 North America Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2027-2032)
  5. 7.2 North America Neurofibromatoses Type II Therapecutics Market Size by Country
  6. 7.2.1 North America Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Neurofibromatoses Type II Therapecutics Market Size by Country (2021-2026)
  8. 7.2.3 North America Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Neurofibromatoses Type II Therapecutics Sales by Country
  2. 8.1.1 Europe Neurofibromatoses Type II Therapecutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026)
  4. 8.1.3 Europe Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Neurofibromatoses Type II Therapecutics Market Size by Country
  6. 8.2.1 Europe Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Neurofibromatoses Type II Therapecutics Market Size by Country (2021-2026)
  8. 8.2.3 Europe Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Neurofibromatoses Type II Therapecutics Sales by Country
  2. 9.1.1 Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Neurofibromatoses Type II Therapecutics Market Size by Country
  6. 9.2.1 Asia-Pacific Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Neurofibromatoses Type II Therapecutics Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Neurofibromatoses Type II Therapecutics Sales by Country
  2. 10.1.1 South America Neurofibromatoses Type II Therapecutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026)
  4. 10.1.3 South America Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2027-2032)
  5. 10.2 South America Neurofibromatoses Type II Therapecutics Market Size by Country
  6. 10.2.1 South America Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Neurofibromatoses Type II Therapecutics Market Size by Country (2021-2026)
  8. 10.2.3 South America Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country
  2. 11.1.1 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size by Country
  6. 11.2.1 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Neurofibromatoses Type II Therapecutics Value Chain Analysis
  2. 12.1.1 Neurofibromatoses Type II Therapecutics Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Neurofibromatoses Type II Therapecutics Production Mode & Process
  7. 12.2 Neurofibromatoses Type II Therapecutics Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Neurofibromatoses Type II Therapecutics Distributors
  10. 12.2.3 Neurofibromatoses Type II Therapecutics Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst